News
06-02-2011, 04:33 AM
AVEO Pharmaceuticals, Inc., today announced data from the final analysis of its Phase 2 randomized discontinuation trial evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with advanced renal cell carcinoma.
More... (http://www.news-medical.net/news/20110602/Data-from-final-analysis-of-AVEOs-tivozanib-Phase-2-trial-in-kidney-cancer-presented-at-ASCO-2011.aspx)
More... (http://www.news-medical.net/news/20110602/Data-from-final-analysis-of-AVEOs-tivozanib-Phase-2-trial-in-kidney-cancer-presented-at-ASCO-2011.aspx)